NCT05694715
Combination Therapy in Cancers With Mutations in DNA Repair Genes
At risk: Primary completion moved 7 months later.
See at-risk trials from University of California, San Francisco
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 7 versions: 5 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Primary and study completion pushed from Jan 31, 2028 to Aug 31, 2028 Show 4 more changesShow less
- Eligibility criteria revised
- Enrollment closed, study ongoing
- Secondary endpoints: details revised at 3 of 4 entries
- Site details revised
- Minor Site contact updatedv6
- Notable Eligibility criteria expanded, about 1 wordv3
- Notable Trial status: Not Yet Recruiting to Recruiting
- Primary and study completion dates: Dec 31, 2027 to Jan 31, 2028
- Start date changed from estimate of Apr 1, 2023 to May 23, 2023
- Site details revised
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (4)
Arms and interventions
Participants will receive a starting dose of 100 mg of niraparib on days 1-7 each 21-day cycle, and 100 mg/m\^2 of irinotecan on day 1 of each 21 day cycle until unacceptable toxicity, disease progression or participant withdrawal.
Participants will receive a starting dose of 200 mg of niraparib on days 1-7 each 21-day cycle, and 100 mg/m\^2 of irinotecan on day 1 of each 21 day cycle until unacceptable toxicity, disease progression or participant withdrawal.
Participants weighing \< 77 kg will receive a starting dose of 200 mg of niraparib on days 1-7 each 21-day cycle, and 100 mg/m\^2 of irinotecan on day 1 of each 21 day cycle until unacceptable toxicity, disease progression or participant withdrawal.
Participants weighing \>= 77 kg will receive a starting dose of 300 mg of niraparib on days 1-7 each 21-day cycle, and 100 mg/m\^2 of irinotecan on day 1 of each 21 day cycle until unacceptable toxicity, disease progression or participant withdrawal.
Participants weighing \< 77 kg will receive a starting dose of 200 mg of niraparib on days 1-7 each 21-day cycle, and 150 mg/m\^2 of irinotecan on day 1 of each 21 day cycle until unacceptable toxicity, disease progression or participant withdrawal.
Participants weighing \>= 77 kg will receive a starting dose of 300 mg of niraparib on days 1-7 each 21-day cycle, and 150 mg/m\^2 of irinotecan on day 1 of each 21 day cycle until unacceptable toxicity, disease progression or participant withdrawal.
Drugs: Niraparib, Irinotecan
Sites
1 site in 1 country
- University of California, San FranciscoSan Francisco, California, United States